Zydus Cadila gets USFDA nod for kidney stones tablets

Tags: Companies
Drug firm Zydus Cadila has received the final approval from the US health regulator to market Potassium Citrate ER tablets used in prevention of kidney stones.

Zydus Cadila has received the final approval from the United States Food and Drug Administration (USFDA) to market Potassium Citrate ER tablets in the strengths of 5 mEq, 10 mEq and 15 mEq, said the Zydus group's listed entity, Cadila Healthcare, said in a statement.

"The estimated sales in 2014 for Potassium Citrate ER tablets is $131.7 million, as per IMS," it added.

The group currently has 94 approvals and has so far filed 239 abbreviated new drug applications (ANDA), Cadila Healthcare said.

Shares of Cadila Healthcare were trading at Rs 1,098.95 per scrip in the afternoon trade on the BSE, up 0.35% from the previous close.

EDITORIAL OF THE DAY

  • It seems India will overtake Germany to emerge as the fourth largest economy globally by 2022

    There is speculation that India will overtake Germany to emerge as the fourth largest economy globally by 2022.

FC NEWSLETTER

Stay informed on our latest news!

TODAY'S COLUMNS

Sandeep Bamzai

Disequilibrium: INDIA’S kill zones

In a curious twist after the 1999 Lok Sabha hustings, ...

Gautam Datt

<b>Newsmaker<b>: Caught in the middle

Historic opportunities can be easily squandered if they are not ...

Kuruvilla Pandikattu

How to cultivate compassion

Imagine the scenario of a fire alarm goes off ...